CYTKNasdaqPharmaceutical PreparationsFiscal year ends December 31
CYTOKINETICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$62.65+0.70 (+1.13%)
Close on Oct 19, 2026
- Market cap
- $8.28M
- P/E (TTM)
- –
- Dividend yield
- –
CYTOKINETICS INC revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License and Milestone Revenues [Member] | $26.93M | $91.28M | $79.35M | $79.35M | $79.35M | $15.00M | $15.00M | – | – | – | – | – | 39.8% | -66.1% |
| Collaboration Revenues [Member] | $10.62M | $9.74M | $8.69M | $7.86M | $6.39M | $4.22M | $3.47M | – | – | – | – | – | 15.7% | +66.3% |
| Research and Development Revenues [Member] | – | – | – | – | – | – | – | $2.22M | $2.13M | $2.75M | $4.03M | $5.32M | – | – |
| Milestone Revenues [Member] | – | – | – | – | – | – | – | $1.00M | $1.00M | $1.00M | $3.50M | $2.50M | – | – |
| Realization of Revenue Participation Right Purchase Agreement [Member] | – | – | – | – | – | – | – | – | – | – | $0 | – | – | – |
By region
From the segment and revenue-disaggregation notes of Cytokinetics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.